Isomorphic Labs, an AI led drug design and discovery company, has secured a funding of $2.1 billion in their second external funding round, to accelerate their efforts to build frontier models that power AI drug design engine (IsoDDE). Isomorphic Labs owned by Demis Hassabis, co-founder of Google Deepmind, claims the funding will help the company in “delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic.”
According to a statement released by Isomorphic Labs, Thrive Capital led the Series B round with support from returning investors Alphabet and GV. MGX, Temasek, CapitalG and the UK Sovereign AI Fund also participated for the first time in this funding round.
💥 Sovereign AI is backing @IsomorphicLabs 💥
Sovereign AI has invested in Isomorphic Labs. Led by Nobel Prize-winner and CEO Sir Demis Hassabis and President Max Jaderberg, Isomorphic is using frontier AI to transform drug discovery, ushering in a new era of biomedical… pic.twitter.com/cWBj6QylS7
— Sovereign AI (@UKSovereignAI) May 12, 2026
Founded in 2021, Isomorphic Labs has quietly been building a platform to accelerate one of the slowest and most expensive processes in science, which is drug discovery. The company’s primary platform, called IsoDDE, will utilize the latest advanced AI technologies capable of predicting the potential actions of a drug long before it reaches clinical trials. The company believes that this will significantly reduce the amount of time required to develop and will also save substantial resources on the delivery of vital therapy to patients.
The fresh capital will help Isomorphic Labs expand its AI drug design engine, grow its international operations, and push more drug candidates toward clinical development. The company is also ramping up hiring across AI research, engineering, and clinical sciences.
“This funding round is a massive vote of confidence in our AI-first approach,” Hassabis said, adding that the company is now focused on scaling its technology to tackle some of the world’s toughest diseases.
Isomorphic Labs has already attracted partnerships with pharmaceutical giants including Novartis, Eli Lilly and Company, and Johnson & Johnson — a sign that big pharma is increasingly betting that the future of medicine will be shaped as much by algorithms as laboratories.
